Keywords: Johnson & Johnson, Incivo, Germany, IQWiG, Hepatitis C, Janssen, Vertex, Incivek, AMNOG

Germany’s IQWiG sees added benefits for Incivo

Article | 24 January 2012

Print This

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal Products ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in